Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 9845175, 9 pages
https://doi.org/10.1155/2017/9845175
Research Article

Increased Levels of sRAGE in Diabetic CKD-G5D Patients: A Potential Protective Mechanism against AGE-Related Upregulation of Fibroblast Growth Factor 23 and Inflammation

1Department of Biomedical Sciences for Health, Università degli Studi di Milano, Via L. Mangiagalli 31, 20133 Milan, Italy
2Laboratory of Molecular Pathology, I.R.C.C.S. Policlinico San Donato, Via R. Morandi 30, San Donato Milanese, 20097 Milan, Italy
3Department of Nephrology, Dialysis and Transplantation, San Bortolo Hospital, Viale Rodolfi 37, 36100 Vicenza, Italy
4International Renal Research Institute Vicenza (IRRIV), San Bortolo Hospital, Viale Rodolfi 37, 36100 Vicenza, Italy
5Service of Laboratory Medicine 1-Clinical Pathology, I.R.C.C.S. Policlinico San Donato, Via R. Morandi 30, San Donato Milanese, 20097 Milan, Italy

Correspondence should be addressed to Elena Dozio; ti.iminu@oizod.anele

Received 22 June 2017; Revised 21 August 2017; Accepted 7 September 2017; Published 25 September 2017

Academic Editor: Carmela R. Balistreri

Copyright © 2017 Elena Dozio et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. J. Collins, R. N. Foley, C. Herzog et al., “United States Renal Data System 2008 annual data report,” American Journal of Kidney Diseases, vol. 53, 1 Supplement, pp. S1–374, 2009. View at Publisher · View at Google Scholar
  2. S. Moe, T. Drüeke, J. Cunningham et al., “Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO),” Kidney International, vol. 69, no. 11, pp. 1945–1953, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Fujii and N. Joki, “Mineral metabolism and cardiovascular disease in CKD,” Clinical and Experimental Nephrology, vol. 21, Supplement 1, pp. 53–63, 2017. View at Publisher · View at Google Scholar
  4. S. Seiler, B. Reichart, D. Roth, E. Seibert, D. Fliser, and G. H. Heine, “FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment,” Nephrology, Dialysis, Transplantation, vol. 25, no. 12, pp. 3983–3989, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. B. D. Parker, L. J. Schurgers, V. M. Brandenburg et al., “The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study,” Annals of Internal Medicine, vol. 152, no. 10, pp. 640–648, 2010. View at Publisher · View at Google Scholar
  6. O. M. Gutierrez, M. Wolf, and E. N. Taylor, “Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the Health Professionals Follow-up Study,” Clinical Journal of the American Society Nephrology, vol. 6, no. 12, pp. 2871–2878, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. M. I. Yilmaz, A. Sonmez, M. Saglam et al., “FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease,” Kidney International, vol. 78, no. 7, pp. 679–685, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Faul, A. P. Amaral, B. Oskouei et al., “FGF23 induces left ventricular hypertrophy,” Journal of Clinical Investigation, vol. 121, no. 11, pp. 4393–4408, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Isakova, P. Wahl, G. S. Vargas et al., “Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease,” Kidney International, vol. 79, no. 12, pp. 1370–1378, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. O. M. Gutiérrez, J. L. Januzzi, T. Isakova et al., “Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease,” Circulation, vol. 119, no. 19, pp. 2545–2552, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Bar, K. Wachter, N. Wege, A. Navarrete Santos, A. Simm, and M. Foller, “Advanced glycation end products stimulate gene expression of fibroblast growth factor 23,” Molecular Nutrition & Food Research, vol. 61, no. 8, 2017. View at Publisher · View at Google Scholar
  12. L. Yan and M. A. Bowman, “Chronic sustained inflammation links to left ventricular hypertrophy and aortic valve sclerosis: a new link between S100/RAGE and FGF23,” Inflammation and Cell Signaling, vol. 1, no. 5, 2014. View at Publisher · View at Google Scholar
  13. R. Kisugi, T. Kouzuma, T. Yamamoto et al., “Structural and glycation site changes of albumin in diabetic patient with very high glycated albumin,” Clinica Chimica Acta, vol. 382, no. 1-2, pp. 59–64, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Dozio, E. Vianello, S. Briganti et al., “Expression of the receptor for advanced glycation end products in epicardial fat: link with tissue thickness and local insulin resistance in coronary artery disease,” Journal of Diabetes Research, vol. 2016, Article ID 2327341, 8 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. S. H. Diepeveen, G. H. Verhoeven, J. van der Palen et al., “Oxidative stress in patients with end-stage renal disease prior to the start of renal replacement therapy,” Nephron. Clinical Practice, vol. 98, no. 1, pp. c3–c7, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Kalousová, M. Hodková, M. Kazderová et al., “Soluble receptor for advanced glycation end products in patients with decreased renal function,” American Journal of Kidney Diseases, vol. 47, no. 3, pp. 406–411, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. P. J. Thornalley, “Advanced glycation end products in renal failure,” Journal of Renal Nutrition, vol. 16, no. 3, pp. 178–184, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Meerwaldt, C. J. Zeebregts, G. Navis, J. L. Hillebrands, J. D. Lefrandt, and A. J. Smit, “Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis,” American Journal of Kidney Diseases, vol. 53, no. 1, pp. 138–150, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Basta, D. Leonardis, F. Mallamaci et al., “Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease,” Kidney International, vol. 77, no. 3, pp. 225–231, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. J. K. Kim, S. Park, M. J. Lee et al., “Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis,” Atherosclerosis, vol. 220, no. 1, pp. 208–214, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Leonardis, G. Basta, F. Mallamaci et al., “Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD),” Nutrition, Metabolism, and Cardiovascular Diseases, vol. 22, no. 9, pp. 748–755, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Koyama, T. Shoji, H. Yokoyama et al., “Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 12, pp. 2587–2593, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Basta, “Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications,” Atherosclerosis, vol. 196, no. 1, pp. 9–21, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. K. M. Choi, H. J. Yoo, H. Y. Kim et al., “Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness,” International Journal of Cardiology, vol. 132, no. 1, pp. 96–101, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. N. Vazzana, F. Santilli, C. Cuccurullo, and G. Davi, “Soluble forms of RAGE in internal medicine,” Internal and Emergency Medicine, vol. 4, no. 5, pp. 389–401, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. H. M. Colhoun, D. J. Betteridge, P. Durrington et al., “Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial,” Diabetes, vol. 60, no. 9, pp. 2379–2385, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Boschetto, I. Campo, M. Stendardo et al., “Plasma sRAGE and N-(carboxymethyl) lysine in patients with CHF and/or COPD,” European Journal of Clinical Investigation, vol. 43, no. 6, pp. 562–569, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. American Diabetes A, “Standards of medical care in diabetes-2015 abridged for primary care providers,” Clinical Diabetes, vol. 33, no. 2, pp. 97–111, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. ESH/ESC Task Force for the Management of Arterial Hypertension, “2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension,” Journal of Hypertension, vol. 31, no. 10, pp. 1925–1938, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Kouzuma, T. Usami, M. Yamakoshi, M. Takahashi, and S. Imamura, “An enzymatic method for the measurement of glycated albumin in biological samples,” Clinica Chimica Acta, vol. 324, no. 1-2, pp. 61–71, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Kouzuma, Y. Uemastu, T. Usami, and S. Imamura, “Study of glycated amino acid elimination reaction for an improved enzymatic glycated albumin measurement method,” Clinica Chimica Acta, vol. 346, no. 2, pp. 135–143, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Kohzuma, T. Yamamoto, Y. Uematsu, Z. K. Shihabi, and B. I. Freedman, “Basic performance of an enzymatic method for glycated albumin and reference range determination,” Journal of Diabetes Science and Technology, vol. 5, no. 6, pp. 1455–1462, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Dozio, N. Di Gaetano, P. Findeisen, and M. M. Corsi Romanelli, “Glycated albumin: from biochemistry and laboratory medicine to clinical practice,” Endocrine, vol. 55, no. 3, pp. 682–690, 2017. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Bellia, M. Zaninotto, C. Cosma et al., “Definition of the upper reference limit of glycated albumin in blood donors from Italy,” Clinical Chemistry and Laboratory Medicine, 2017. View at Publisher · View at Google Scholar
  35. R. Testa, F. Ceriotti, E. Guerra et al., “Glycated albumin: correlation to HbA1c and preliminary reference interval evaluation,” Clinical Chemistry and Laboratory Medicine, vol. 55, no. 2, pp. e31–ee3, 2017. View at Publisher · View at Google Scholar
  36. E. Dozio, S. Briganti, A. Delnevo et al., “Relationship between soluble receptor for advanced glycation end products (sRAGE), body composition and fat distribution in healthy women,” European Journal of Nutrition, 2016. View at Publisher · View at Google Scholar · View at Scopus
  37. P. Stenvinkel and T. E. Larsson, “Chronic kidney disease: a clinical model of premature aging,” American Journal of Kidney Diseases, vol. 62, no. 2, pp. 339–351, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Ramasamy, S. F. Yan, K. Herold, R. Clynes, and A. M. Schmidt, “Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis,” Annals of the New York Academy of Sciences, vol. 1126, pp. 7–13, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. L. van Heerebeek, N. Hamdani, M. L. Handoko et al., “Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension,” Circulation, vol. 117, no. 1, pp. 43–51, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. F. Wu, J. Z. Feng, Y. H. Qiu et al., “Activation of receptor for advanced glycation end products contributes to aortic remodeling and endothelial dysfunction in sinoaortic denervated rats,” Atherosclerosis, vol. 229, no. 2, pp. 287–294, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. A. E. Stinghen, Z. A. Massy, H. Vlassara, G. E. Striker, and A. Boullier, “Uremic toxicity of advanced glycation end products in CKD,” Journal of the American Society of Nephrology, vol. 27, no. 2, pp. 354–370, 2016. View at Publisher · View at Google Scholar · View at Scopus
  42. O. M. Gutierrez, “Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the “trade-off” hypothesis,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 9, pp. 1710–1716, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Challier, S. Jacqueminet, O. Benabdesselam, A. Grimaldi, and J. L. Beaudeux, “Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes,” Clinical Chemistry, vol. 51, no. 9, pp. 1749-1750, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. K. Nakamura, S. Yamagishi, H. Adachi et al., “Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease,” Diabetes/Metabolism Research and Reviews, vol. 23, no. 5, pp. 368–371, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. K. Nakamura, S. Yamagishi, H. Adachi et al., “Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes,” Microvascular Research, vol. 76, no. 1, pp. 52–56, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. M. C. Thomas, M. Woodward, B. Neal et al., “Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes,” Diabetes Care, vol. 38, no. 10, pp. 1891–1897, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. J. W. Hartog, A. A. Voors, S. J. Bakker, A. J. Smit, and D. J. van Veldhuisen, “Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications,” European Journal of Heart Failure, vol. 9, no. 12, pp. 1146–1155, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Raposeiras-Roubín, B. K. Rodiño-Janeiro, L. Grigorian-Shamagian et al., “Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: new roles for soluble RAGE,” European Journal of Heart Failure Eur J Heart Fail., vol. 12, no. 10, pp. 1092–1100, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. L. Viaene, B. Bammens, B. K. Meijers, Y. Vanrenterghem, D. Vanderschueren, and P. Evenepoel, “Residual renal function is an independent determinant of serum FGF-23 levels in dialysis patients,” Nephrology, Dialysis, Transplantation, vol. 27, no. 5, pp. 2017–2022, 2012. View at Publisher · View at Google Scholar
  50. S. H. Diepeveen, G. H. Verhoeven, J. van der Palen et al., “The effect of the initiation of renal replacement therapy on lipid profile and oxidative stress during the first 6 months of treatment,” Clinica Chimica Acta, vol. 361, no. 1-2, pp. 112–118, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. K. Inoue, A. Goto, M. Kishimoto et al., “Possible discrepancy of HbA1c values and its assessment among patients with chronic renal failure, hemodialysis and other diseases,” Clinical and Experimental Nephrology, vol. 19, no. 6, pp. 1179–1183, 2015. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Yazdanpanah, M. Rabiee, M. Tahriri et al., “Evaluation of glycated albumin (GA) and GA/HbA1c ratio for diagnosis of diabetes and glycemic control: a comprehensive review,” Critical Reviews in Clinical Laboratory Sciences, vol. 54, no. 4, pp. 219–232, 2017. View at Publisher · View at Google Scholar
  53. Y. Koyama, Y. Takeishi, T. Niizeki et al., “Soluble receptor for advanced glycation end products (RAGE) is a prognostic factor for heart failure,” Journal of Cardiac Failure, vol. 14, no. 2, pp. 133–139, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Raposeiras-Roubín, B. K. Rodiño-Janeiro, L. Grigorian-Shamagian et al., “Relation of soluble receptor for advanced glycation end products to predict mortality in patients with chronic heart failure independently of Seattle heart failure score,” The American Journal of Cardiology, vol. 107, no. 6, pp. 938–944, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. L. J. Wang, L. Lu, F. R. Zhang, Q. J. Chen, R. De Caterina, and W. F. Shen, “Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure,” European Journal of Heart Failure, vol. 13, no. 4, pp. 440–449, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Lazo, M. K. Halushka, L. Shen et al., “Soluble receptor for advanced glycation end products and the risk for incident heart failure: the Atherosclerosis Risk in Communities study,” American Heart Journal, vol. 170, no. 5, pp. 961–967, 2015. View at Publisher · View at Google Scholar · View at Scopus